All desks
Tracker
33 dated events, newest first. Each links to its source records. Filter by desk, or download the CSV (CC BY 4.0). Every FDA warning letter in the log is also in one table: FDA warning letters to peptide sellers.
Showing 33
-
2026
- Market
NSW Health reports 1,180 peptide-linked emergency visits
NSW Health surveillance data counted 1,180 emergency department presentations associated with peptide use from July 2025 to September 2026, rising from five a month to more than 217. Coverage of the report said retatrutide was mentioned in 833.
Sources: NSW Government ministerial release, Oct 19, 2026 · Newcastle Herald, Oct 19, 2026
- Courts
Lilly dismisses retatrutide suits against Texas Peptides and Lone Star Peptide
Eli Lilly filed notices of voluntary dismissal with prejudice on Oct 15 (W.D. Tex.) and Oct 16 (S.D. Tex.), before either seller answered. The notices give no reason.
Sources: Notice of dismissal, Texas Peptides (W.D. Tex. 5:26-cv-05146) · Notice of dismissal, Lone Star Peptide (S.D. Tex. 4:26-cv-06562)
- Regulation
CSPI urges FDA to reject July peptide votes
Letter to Acting Commissioner Kyle Diamantas cites FDA staff recommendations against all seven peptides and members’ reported financial ties.
Source: CSPI press release, Oct 14, 2026
- Regulation
Peptide compounding 'interim access policy' goes to White House review
OMB's dashboard shows FDA's 'Interim Access Policy for Compounding Using Certain Peptides' (RIN 0910-ZD94) received October 14, 2026. Not final.
Sources: Reginfo.gov EO 12866 review · POLITICO, Oct 16, 2026
- Courts
Jury convicts Pinned Aminos seller
Ryan Fields convicted of misbranded-drug and money-laundering conspiracies over sites that labeled drugs "research compounds."
- Enforcement
FDA sends warning letters to five online peptide sellers
Royal Peptides, Tex Peptides, NuScience Peptides, Peak Performance Peptides and Peptide Partners. Bacteriostatic water was itself named as an unapproved drug.
Sources: FDA warning letter: Peptide Partners LLC (735063) · FDA warning letter: Royal Peptides LLC (734884)
- Courts
Paradigm Peptides owner sentenced to 70 months
A federal judge in South Bend sentenced Matthew Kawa to 5 years 10 months; his sister received 16 months.
Sources: DOJ case page · CBS News
- Regulation
Panel backs Semax and Epitalon, rejects emideltide (DSIP)
Semax passed 8-5. Emideltide failed 6 yes to 7 no. Reported tallies for Epitalon differ between sources.
Sources: AJMC · SSRP Institute vote summary
- Regulation
FDA advisers back BPC-157, KPV, TB-500 and MOTS-c for 503A list
Advisory votes of 8-6 (BPC-157, KPV, TB-500) and 7-5 (MOTS-c). The votes are nonbinding.
Sources: FDA meeting page · AJMC
- Courts
Michigan man sentenced to 21 months for 'research' GLP-1 sales
Brandon Piper sold China-sourced semaglutide and tirzepatide labeled "for research purposes only" via MilestonePurity.com.
- Regulation
Louisiana enacts Act 374 on compounded peptides
Licensing boards may not block prescribers or pharmacists using federally compliant 503A/503B peptide compounding. Effective August 1, 2026.
- Regulation
Federal Register notice schedules PCAC review of seven peptides
91 Fed. Reg. 20465 announced the July 23-24 advisory committee meeting on BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon.
- Regulation
FDA to remove 12 peptides from 503A Category 2
FDA said the substances would leave Category 2 after seven days because their nominations were withdrawn. Removal does not put them on the 503A bulks list.
Sources: Polsinelli, April 22, 2026 · FDA Category 2 page
- Regulation
FDA plans PCAC review of LL-37, GHK-Cu, dihexa, Melanotan II and PEG-MGF
Early announcement: meeting before the end of February 2027. Date, docket and briefing documents not yet published.
Source: FDA: Meeting of the PCAC (2027)
- Courts
Utah physician indicted over China-sourced peptides
A federal grand jury indicted a Utah osteopathic physician on misbranded-drug charges. An indictment is an allegation; the defendant is presumed innocent.
- Enforcement
FDA warns Gram Peptides and Prime Sciences over retatrutide
Letters dated March 31, 2026 name retatrutide, tirzepatide and bacteriostatic water among unapproved new drugs.
Sources: FDA warning letter: Gram Peptides (721806) · FDA warning letter: Prime Sciences (721805)
- Market
Peptide Sciences announces voluntary shutdown
peptidesciences.com replaced its storefront with a notice saying the company had decided to voluntarily shut down and discontinue its research products. No reason given.
Sources: The Peptide List, March 6, 2026 · TitrateLab archive review
- Regulation
Kennedy on Joe Rogan: 'I'm a big fan of peptides'
The HHS Secretary said he hoped about 14 peptides would be moved to a place where people have access from ethical suppliers.
Source: NPR, March 26, 2026
- Regulation
FDA says it will restrict GLP-1 APIs for mass-marketed compounded drugs
Commissioner Makary's statement named Hims & Hers and barred 'generic' or 'same as' claims, warning of seizure and injunction without further notice.
Source: FDA statement, Feb 6, 2026
- Market
Science.bio posts permanent closure notice
Science.bio's site now reads 'Permanently Closed' and says it has discontinued the sale of research products.
Source: Science.bio closure page
-
-
2025
- Courts
Paradigm Peptides owner and sister plead guilty
DOJ's case page says Matthew Kawa and Jennifer Stechkober pleaded guilty on December 10, 2025.
- Regulation
WADA publishes 2026 Prohibited List
BPC-157 stays named under S0; S2 examples include AOD-9604, CJC-1295, ipamorelin and TB-500; MOTS-c under S4. In force January 1, 2026.
- Enforcement
FDA warning letters to online sellers of compounded GLP-1s and retatrutide
Letters dated September 9, 2025, including one to GLP-1 Solution, cited retatrutide as an unapproved new drug and called some compounded semaglutide and tirzepatide claims false or misleading.
- Regulation
503A wind-down for compounded semaglutide copies ends
The end of the 60-day period FDA announced on February 21, 2025 for state-licensed pharmacies compounding essentially-copies of semaglutide injection.
- Courts
Kentucky doctor pleads guilty over research-labeled semaglutide
Ashland physician Matthew Lewis admitted giving patients non-approved semaglutide, some labeled for lab research, bought from unregistered suppliers.
- Enforcement
FDA warning letter to USApeptide.com
FDA said the Germany-listed site sold unapproved, misbranded semaglutide and tirzepatide to US consumers despite 'research use only' statements.
- Regulation
FDA declares semaglutide injection shortage resolved
FDA said semaglutide had been in shortage since 2022. 503A compounders got until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 before FDA would act on shortage-dependent copies.
Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
-
-
2024
- Regulation
FDA declares tirzepatide injection shortage resolved
FDA re-evaluated its October 2024 decision and determined the tirzepatide injection shortage was resolved, starting wind-down periods for compounders.
Source: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Enforcement
FDA warns research-chemical sellers of semaglutide and retatrutide
FDA warning letters dated December 10, 2024 went to Swisschems and Summit Research Peptides, among others, saying 'research use only' labels did not change the products' status as unapproved new drugs.
Sources: FDA warning letter: Swisschems (695663) · FDA warning letter: Summit Research Peptides (695607)
- Regulation
FDA advisers reject CJC-1295, AOD-9604 and thymosin alpha-1
PCAC votes: every CJC-1295 form failed (0-13; acetate 1-12), AOD-9604 0-12, thymosin alpha-1 4-17.
- Regulation
FDA advisers vote against ipamorelin, kisspeptin-10 and ibutamoren
The Pharmacy Compounding Advisory Committee voted against adding ipamorelin (0-12), kisspeptin-10 (0-11), ibutamoren (1-13) and L-theanine (1-12) to the 503A bulks list.
- Market
Paradigm Peptides website goes offline
CBS News reports Paradigm Peptides was shut down in March 2024. DOJ's victim notice covers purchases from April 2019 to March 2024. (Day of month not published; shown as the 1st.)
Sources: CBS News, July 30, 2026 · DOJ N.D. Ind.: United States v. Matthew Kawa
-
-
2023
- Regulation
FDA places peptide bulk substances in compounding Category 2
FDA's Category 2 table lists September 29, 2023 as the date several peptide-related substances (including GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10) were added. A law-firm review counts 19 peptide or peptide-related substances placed in Category 2 during 2023.
Sources: FDA: Certain bulk drug substances that may present significant safety risks · Polsinelli: What FDA's latest actions mean for peptide compounding (Apr 22, 2026)
-